Domestic pharmaceutical company Dabur Oncology Plc has received the approval from US Food and Drug Administrator (USFDA) for selling 'Mitoxantrone Hydrochloride', an injectable used in the treatment of prostate cancer.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>According to the information available on USFDA's website, company has received the approval for the injectable Mitoxantrone Hydrochloride in different strengths.</P>
</p><p class='TableClas'>Dabur Pharma Ltd operates in Europe and other overseas markets through its fully-owned subsidiary, Dabur Oncology Plc.<BR></P></p><p class='TableClas'></p></table>


Dabur gets USFDA's nod for cancer drug

Also Read

Gemini targets acquisition in security space

Suzlon Q4 FY08 net profit at Rs 482.55 cr

Refractory brick laying inaugurated

Telelogic announce two enhancements

SMEs to get major boost under CGTMSE

Explore News